<DOC>
	<DOCNO>NCT00216463</DOCNO>
	<brief_summary>The aim study assess safety tolerability vary dose load regimens ISIS 301012 people elevate LDL-cholesterol level .</brief_summary>
	<brief_title>Safety Tolerability Varying Load Dose ISIS 301012 People With Elevated LDL-cholesterol Levels</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Mipomersen</mesh_term>
	<criteria>BMI &gt; /= 25 &lt; /= 32 kg/m^2 fast stable LDLcholesterol &gt; /= 130 mg/dL ( 3.36 mmol/L ) triglycerides &lt; 400 mg/dL ( 4.55 mmol/L ) Females childbearing potential No endocrine , hematologic , renal , hepatic , metabolic , psychiatric , neurology , pulmonary cardiovascular disease Subjects test positive hepatitis B , C HIV Current diagnosis know history liver disease , acute chronic hepatitis , liver cirrhosis , liver steatosis , liver function abnormality AST , ALT , GGT , total bilirubin &gt; /= 1.5 x ULN Screening A systolic blood pressure &gt; /= 160 mmHg diastolic blood pressure &gt; /= 95 mmHg 2 occasion Screening Concomitant medication within 14 day dose , except hormone replacement therapy postmenopausal woman acetylsalicylic acid paracetamol dose few five consecutive day Subject take lipidlowering drug within 30 day five halflives ( lipidlowering drug ) whichever long , prior Screening Alcohol drug abuse within 2 year Screening Donated blood ( 450 mL ) within 3 month prior Screening suffer significant blood loss equal blood donor portion Subject smoke &gt; 10 cigarette , one pipe one cigar per day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>LDL-cholesterol</keyword>
	<keyword>apoB-100</keyword>
	<keyword>apoB-48</keyword>
</DOC>